



National Securities Market Commission  
Markets Directorate General  
C/ Edison núm. 4  
28006 Madrid

Colmenar Viejo (Madrid), July 10, 2017

Pursuant to article 228 of the restated text of the Securities Market Law, we hereby inform you of the following **SIGNIFICANT EVENT**:

In compliance with the provision of section 2 of Rule Fourth of Circular 1/2017, of 26 April, of the National Securities Market Commission, on liquidity agreements, the Company announces that on July 10, 2017 has entered into a liquidity agreement (the “**Liquidity Agreement**”) with MEDIACIÓN BURSÁTIL, SOCIEDAD DE VALORES, S.A. (the “**Financial Intermediary**”), in order to favor liquidity of transactions and the regularity of trading of their shares.

Pursuant to section 2 a) of said Rule Fourth, the following information is reported:

- Shares of the Liquidity Agreement: PHARMA MAR Shares with ISIN ES0169501030.
- Markets in which operations will take place: The operations will be carried out in the regulated markets and in the Spanish multilateral trading systems, through the open market.
- Contract Term: 12 months, counting from July 11, 2017, being understood tacitly extended for an equal period, unless otherwise indicated by one of the parties.
- Number of shares allocated to the securities account associated with the Liquidity Agreement: 339,537 shares.
- Amount allocated to the cash account associated with the Liquidity Agreement: EUR 1,303,821.15.